A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

Affiliations

• ¹ Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
• ² Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
• ³ Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
• ⁴ Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Walter Reed National Military Medical Center, National Institutes of Health, Bethesda, MD, USA.
• ⁵ Dept. of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
• ⁶ Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
• ⁷ Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA landgrec@mskcc.org.